Amgen, Inc.
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 1980-01-01
- Employees
- 26.7K
- Market Cap
- $175.6B
- Website
- http://www.amgen.com
An Open-label Study to Evaluate the Effect of Treatment With Romosozumab or Teriparatide in Postmenopausal Women
Phase 3
Completed
- Conditions
- Postmenopausal Osteoporosis
- Interventions
- Drug: Romozosumab
- First Posted Date
- 2013-02-21
- Last Posted Date
- 2022-11-29
- Lead Sponsor
- Amgen
- Target Recruit Count
- 436
- Registration Number
- NCT01796301
- Locations
- 🇬🇧
Research Site, Sidcup, United Kingdom
Phase 1/1b Study of Rilotumumab in Japanese Subjects With Advanced Solid Tumors or Advanced or Metastatic Gastric or GEJ
Phase 1
Completed
- Conditions
- Part 1- Advanced Solid TumorsPart 2- Advanced or Metastatic Gastric CancerPart 2- Advanced or Metastatic GEJ
- Interventions
- First Posted Date
- 2013-02-15
- Last Posted Date
- 2016-02-29
- Lead Sponsor
- Amgen
- Target Recruit Count
- 21
- Registration Number
- NCT01791374
- Locations
- 🇯🇵
Research Site, Suntou-gun, Shizuoka, Japan
Medical Records Review to Describe the Patterns of KRAS Testing and Vectibix Use in Europe
Completed
- Conditions
- Metastatic Colorectal Cancer
- Interventions
- Other: Other
- First Posted Date
- 2013-02-15
- Last Posted Date
- 2022-09-10
- Lead Sponsor
- Amgen
- Target Recruit Count
- 439
- Registration Number
- NCT01791361
- Locations
- 🇸🇪
Research Site, Västerås, Sweden
Efficacy and Safety of Etelcalcetide (AMG 416) in the Treatment of Secondary Hyperparathyroidism (SHPT) in Patients With Chronic Kidney Disease (CKD) on Hemodialysis
Phase 3
Completed
- Conditions
- Hyperparathyroidism, Secondary
- Interventions
- Drug: Placebo
- First Posted Date
- 2013-02-11
- Last Posted Date
- 2019-08-20
- Lead Sponsor
- Amgen
- Target Recruit Count
- 515
- Registration Number
- NCT01788046
- Locations
- 🇸🇪
Research Site, Uppsala, Sweden
Efficacy and Safety of Etelcalcetide (AMG 416) in the Treatment of Secondary Hyperparathyroidism (SHPT) in Patients With Chronic Kidney Disease on Hemodialysis
Phase 3
Completed
- Conditions
- Hyperparathyroidism, Secondary
- Interventions
- Drug: Placebo
- First Posted Date
- 2013-02-07
- Last Posted Date
- 2019-08-26
- Lead Sponsor
- Amgen
- Target Recruit Count
- 508
- Registration Number
- NCT01785849
- Locations
- 🇬🇧
Research Site, Sheffield, United Kingdom
Extension Study of Etelcalcetide in the Treatment of Secondary Hyperparathyroidism (SHPT) in Patients With Chronic Kidney Disease (CKD) on Hemodialysis
- First Posted Date
- 2013-02-07
- Last Posted Date
- 2019-04-10
- Lead Sponsor
- Amgen
- Target Recruit Count
- 891
- Registration Number
- NCT01785875
- Locations
- 🇬🇧
Research Site, Sheffield, United Kingdom
Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk
Phase 3
Completed
- Conditions
- Dyslipidemia
- Interventions
- Biological: EvolocumabDrug: Placebo
- First Posted Date
- 2013-01-09
- Last Posted Date
- 2024-05-28
- Lead Sponsor
- Amgen
- Target Recruit Count
- 27564
- Registration Number
- NCT01764633
- Locations
- 🇬🇧
Research Site, York, United Kingdom
Reduction of LDL-C With PCSK9 Inhibition in Heterozygous Familial Hypercholesterolemia Disorder Study-2
Phase 3
Completed
- Conditions
- Hyperlipidemia
- Interventions
- Drug: PlaceboBiological: Evolocumab
- First Posted Date
- 2013-01-09
- Last Posted Date
- 2019-06-17
- Lead Sponsor
- Amgen
- Target Recruit Count
- 331
- Registration Number
- NCT01763918
- Locations
- 🇬🇧
Research Site, Manchester, United Kingdom
Monoclonal Antibody Against PCSK9 to Reduce Elevated LDL-C in Subjects Currently Not Receiving Drug Therapy for Easing Lipid Levels-2
Phase 3
Completed
- Conditions
- Hyperlipidemia
- Interventions
- First Posted Date
- 2013-01-09
- Last Posted Date
- 2022-11-08
- Lead Sponsor
- Amgen
- Target Recruit Count
- 615
- Registration Number
- NCT01763827
- Locations
- 🇹🇷
Research Site, Istanbul, Turkey
Goal Achievement After Utilizing an Anti-PCSK9 Antibody in Statin Intolerant Subjects -2
Phase 3
Completed
- Conditions
- Hyperlipidemia
- Interventions
- First Posted Date
- 2013-01-09
- Last Posted Date
- 2020-07-20
- Lead Sponsor
- Amgen
- Target Recruit Count
- 307
- Registration Number
- NCT01763905
- Locations
- 🇬🇧
Research Site, West Bromwich, United Kingdom
© Copyright 2025. All Rights Reserved by MedPath